Here's a quick sketch of the Wall Street gossip mill emerging from the 'Liver Meeting.'
A Dendreon agreement calls for a financial restructuring of the company in which the bondholders will receive equity for the debt owed, potentially wiping out current equity shareholders.
Based on promising results from a small study, Sage expects to start a larger phase III study of its anti-seizure drug next year.
A triple therapy combining two experimental Merck drugs with Gilead's Sovaldi yielded interim hepatitis C cure rates for ranging from 80% to 87% following six to eight weeks of treatment.
A deeply flawed FDA advisory panel voted to support Rockwell's iron replacement therapy for dialysis. FDA still must decide if the product is approvable.
Salix Pharmaceuticals has been rocked by an accounting scandal involving inventory levels of its key gastrointestinal drugs, forcing the company to cut financial forecasts for the rest of the year.
The new clinical data on Bluebird's gene therapy are contained in a just-released abstract ahead of next month's American Society of Hematology annual meeting.
New results from a study of Epizyme's leukemia drug were disclosed ahead of next month's American Society of Hematology annual meeting.
The new imetelstat data in myelofibrosis are contained in a just-released research abstract ahead of next month's American Society of Hematology ASH annual meeting.
Aegerion Pharmaceuticals is spending $325 million, or almost all of its cash, to purchase a recently approved, orphan-disease drug from AstraZeneca.